Controller

Chemours Investigation: Kessler Topaz Meltzer & Check, LLP Investigates The Chemours Company (NYSE: CC) for Potential Securities Violations and Encourages Investors with Significant Losses to Contact the Firm

Retrieved on: 
Friday, March 8, 2024

RADNOR, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) (“Chemours”).

Key Points: 
  • RADNOR, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) (“Chemours”).
  • If you are a Chemours investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP : Jonathan Naji, Esq.
  • For more information about Kessler Topaz Meltzer & Check, LLP , please visit www.ktmc.com .
  • Kessler Topaz Meltzer & Check, LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC).
  • The investigation concerns whether Chemours and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

ThreeD Capital Inc. Releases Results For the Three and Six Months Ended December 31, 2023

Retrieved on: 
Thursday, February 29, 2024

During this past quarter, ThreeD benefited from its strategic investments in digital assets as the Company was able to realize strong gains on these investments.

Key Points: 
  • During this past quarter, ThreeD benefited from its strategic investments in digital assets as the Company was able to realize strong gains on these investments.
  • Lancaster will continue its service agreement with the Company to provide accounting and corporate secretarial services.
  • Pursuant to the services agreement with Lancaster, ThreeD has appointed Matthew Davis, CPA, as Chief Financial Officer and Corporate Secretary of the Company to replace Mr. Chapman’s.
  • Use of Non-GAAP Financial Measures:
    This press release contains references to “net asset value per share” (“NAV”) which is a non-GAAP financial measure.

CC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages The Chemours Company (NYSE: CC) Investors with Significant Losses to Contact the Firm

Retrieved on: 
Thursday, February 29, 2024

RADNOR, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) (“Chemours”).

Key Points: 
  • RADNOR, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) (“Chemours”).
  • If you are a Chemours investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP : Jonathan Naji, Esq.
  • For more information about Kessler Topaz Meltzer & Check, LLP , please visit www.ktmc.com .
  • Kessler Topaz Meltzer & Check, LLP

CC NEWS: Johnson Fistel has Commenced a Class Action Investigation Following Chemours CEO, CFO on Leave and Delaying 10-K

Retrieved on: 
Thursday, February 29, 2024

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether The Chemours Company (“Chemours” or “the Company”) (NYSE: CC).

Key Points: 
  • SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether The Chemours Company (“Chemours” or “the Company”) (NYSE: CC).
  • or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.
  • The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
  • If you purchased securities and suffered significant losses on your investment, join our investigation now:
    There is no cost or obligation to you.

Charlotte Hanneman to succeed Abhijit Bhattacharya as Philips’ Chief Financial Officer (CFO)

Retrieved on: 
Wednesday, February 28, 2024

The proposal will be submitted to the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024.

Key Points: 
  • The proposal will be submitted to the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024.
  • Ms. Hanneman will join Philips as a member of Philips’ Executive Committee on June 1, 2024, to start her induction and transition into the role, succeeding current CFO Abhijit Bhattacharya on October 1, 2024.
  • In this current role, she is responsible for financial control, enterprise financial planning and analysis, and business development finance.
  • I am fully focused on delivering on Philips’ plan in the next six months and ensuring a seamless handover to Charlotte.”

Safety Shot Appoints New CFO Danielle De Rosa

Retrieved on: 
Tuesday, February 27, 2024

JUPITER, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced it has appointed Danielle De Rosa as its new Chief Financial Officer effective March 1, 2024. Ms. Rosa is a multifaceted, analytical, and results-driven professional with more than 25 years of experience in all aspects of financial services and operational functions including serving as a public company CFO.

Key Points: 
  • JUPITER, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced it has appointed Danielle De Rosa as its new Chief Financial Officer effective March 1, 2024.
  • “With the national launch of our highly anticipated functional beverage, Safety Shot, our revenue and operations structure are changing rapidly.
  • Ms. De Rosa served as CFO of VirTra where she was responsible for all operations and finance functions including managing over 50 staff members.
  • Ms. De Rosa replaces Markita Russell, who will return to her roll as Controller of Safety Shot and of SRM Entertainment, a spin-out of Safety Shot (formerly Jupiter Wellness).

Ocean Power Technologies to Report fiscal 2024 Third Quarter Results on March 13, 2024

Retrieved on: 
Wednesday, February 21, 2024

MONROE TOWNSHIP, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it will report its fiscal 2024 third quarter for the period ended January 31, 2024, results after the market closes on Wednesday March 13, 2024.

Key Points: 
  • MONROE TOWNSHIP, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it will report its fiscal 2024 third quarter for the period ended January 31, 2024, results after the market closes on Wednesday March 13, 2024.
  • A conference call to discuss OPT’s financial results will be Thursday March 14, 2024, 9:00am EDT.
  • You may access the replay by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers and using the Conference ID 13742581.
  • In an effort to increase relations with institutional investors, OPT management has dedicated time to hosting individual meetings with portfolio managers and analysts.

Ocean Power Technologies to Report fiscal 2024 Third Quarter Results on March 13, 2024

Retrieved on: 
Wednesday, February 21, 2024

MONROE TOWNSHIP, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it will report its fiscal 2024 third quarter for the period ended January 31, 2024, results after the market closes on Wednesday March 13, 2024.

Key Points: 
  • MONROE TOWNSHIP, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it will report its fiscal 2024 third quarter for the period ended January 31, 2024, results after the market closes on Wednesday March 13, 2024.
  • A conference call to discuss OPT’s financial results will be Thursday March 14, 2024, 9:00am EDT.
  • You may access the replay by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers and using the Conference ID 13742581.
  • In an effort to increase relations with institutional investors, OPT management has dedicated time to hosting individual meetings with portfolio managers and analysts.

RenovoRx Highlights Key Leadership Promotions

Retrieved on: 
Friday, March 8, 2024

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.
  • Since joining RenovoRx, Ms. Gentry has demonstrated exemplary leadership and commitment to advancing the Company’s clinical pipeline.
  • Mr. Kocak has been promoted to the position of Principal Accounting Officer and will retain his roles as Vice President and Controller of RenovoRx.
  • In this new leadership role, Mr. Kocak will oversee all financial management, reporting and strategic planning initiatives crucial to furthering the Company’s research and development efforts.